Tekla Capital Management’s Gilead Sciences GILD Stock Holding History

Tekla Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-57,400	Closed	-$4.79M	–	149
2016 Q2	$4.79M	Buy	+57,400	New	+$5.09M	0.2%	90
2015 Q2	–	Sell	-430,100	Closed	-$42.2M	–	125
2015 Q1	$42.2M	Buy	430,100 +429,139	+44,655%	+$43.6M	1.67%	16
2014 Q4	$91K	Sell	961 -159,939	-99%	-$16.5M	﹤0.01%	92
2014 Q3	$17.1M	Buy	+160,900	New	+$15.8M	0.8%	32

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tekla Capital Management's GILD Position: Q2 2023 in Review

Tekla Capital Management reduced its Gilead Sciences (GILD) stake by 1.7% in Q2 2023, selling an estimated $2.07M and leaving 1,533,884 shares worth $118M. The position accounts for 4.63% of the portfolio, ranked #3.

Tekla Capital Management first reported a position in GILD in Q2 2013 and has held it in 41 quarters since. The position peaked at $265M in Q3 2014. 1,702 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

Tekla Capital Management held 1,533,884 shares of Gilead Sciences worth $118M as of Q2 2023.
Tekla Capital Management sold 26,000 Gilead Sciences shares in Q2 2023, an estimated $2.07M.
Gilead Sciences made up 4.63% of Tekla Capital Management's portfolio in Q2 2023, its #3 holding.
Tekla Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 41 quarters since.
Tekla Capital Management's Gilead Sciences position peaked at $265M in Q3 2014.
1,702 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.